Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan/Ligand initiates 10 ALRT1057 oral retinoid Phase IIb trials.

Executive Summary

LIGAND/ALLERGAN INITIATE 10 ALRT1057 PHASE IIb TRIALS using the oral 9-cis-retinoic acid compound, Irvine, Calif.-based Allergan and San Diego-based Ligand announced May 23. The compound will be studied in non-Hodgkin's lymphomas, renal cell carcinoma (two studies of ALRT1057 plus alpha interferon), squamous cell carcinoma of the head and neck (ALRT1057 plus cisplatin), ovarian cancer (ALRT1057 plus cisplatin), patients with HIV (with the National Cancer Institute), AIDS-related Kaposi's sarcoma, hormone refractory prostate cancer, acute promyelocytic leukemia and multiple myeloma. Phase II trials are ongoing for a topical formulation for KS and mycosis fungoides.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel